Related references
Note: Only part of the references are listed.Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology
Stefan Baenziger et al.
BLOOD (2009)
NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model
Calin D. Dumitru et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation
Alexandre Larange et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Antitumor Effects of an Imidazoquinoline in Renal Cell Carcinoma
Michael J. Schwartz et al.
UROLOGY (2009)
A phase II dose-ranging study of topical resiquimod to treat actinic keratosis
R. -M. Szeimies et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma
Reinhard Dummer et al.
CLINICAL CANCER RESEARCH (2008)
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer
Christian Manegold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy
Evelien L. J. M. Smits et al.
ONCOLOGIST (2008)
Pharmacokinetics of 852A, an imidazoquinoline toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans
Lester I. Harrison et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Immune surveillance of tumors
Jeremy B. Swann et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Development of TLR9 agonists for cancer therapy
Arthur M. Krieg
JOURNAL OF CLINICAL INVESTIGATION (2007)
Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma
Mikhail Pashenkov et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma
Brian K. Link et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists
Kevin S. Gorski et al.
INTERNATIONAL IMMUNOLOGY (2006)
Imiquimod for actinic keratosis: Systematic review and meta-analysis
Gina Hadley et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
How Toll-like receptors signal: what we know and what we don't know
LAJ O'Neill
CURRENT OPINION IN IMMUNOLOGY (2006)
Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting toll-like receptor 9
Hui Wang et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
A Carpentier et al.
NEURO-ONCOLOGY (2006)
Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion
M Gunzer et al.
BLOOD (2005)
TLR11 activation of dendritic cells by a protozoan profilin-like protein
F Yarovinsky et al.
SCIENCE (2005)
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma:: results from a randomized vehicle-controlled phase III study in Europe
HJ Schulze et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis - Results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials
N Korman et al.
ARCHIVES OF DERMATOLOGY (2005)
Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors
A Takaoka et al.
NATURE (2005)
Synthetic TLR Agonists reveal functional differences between human TLR7 and TLR8
KB Gorden et al.
JOURNAL OF IMMUNOLOGY (2005)
Toll-like receptors in innate immunity
K Takeda et al.
INTERNATIONAL IMMUNOLOGY (2005)
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies
J Geisse et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Recognition of single-stranded RNA viruses by Toll-like receptor 7
JM Lund et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
SS Diebold et al.
SCIENCE (2004)
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
F Heil et al.
SCIENCE (2004)
Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6
T Kawai et al.
NATURE IMMUNOLOGY (2004)
Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity
MM Whitmore et al.
CANCER RESEARCH (2004)
Interferons, interferon-like cytokines, and their receptors
S Pestka et al.
IMMUNOLOGICAL REVIEWS (2004)
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities
J Vollmer et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Immunopharmacology of CpG oligodeoxynucleotides and ribavirin
J Vollmer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-Class CpG oligodeoxynucleotide TLR9 agonist
AM Krieg et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling
K Honda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology
RM Szeimies et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Expression and function of toll-like receptors in eosinophils: Activation by toll-like receptor 7 ligand
H Nagase et al.
JOURNAL OF IMMUNOLOGY (2003)
Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7
J Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily
F Heil et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion
W Sterry et al.
BRITISH JOURNAL OF DERMATOLOGY (2002)
A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses
E Stockfleth et al.
ARCHIVES OF DERMATOLOGY (2002)
Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model
K Heckelsmiller et al.
JOURNAL OF IMMUNOLOGY (2002)
Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread
S Ugurel et al.
BRITISH JOURNAL OF DERMATOLOGY (2002)
Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins
O Takeuchi et al.
JOURNAL OF IMMUNOLOGY (2002)
CpG DNA: recognition by and activation of monocytes
DM Klinman et al.
MICROBES AND INFECTION (2002)
Interferon-α and interleukin-12 are induced differentially by toll-like receptor 7 ligands in human blood dendritic cell subsets
T Ito et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides
V Hornung et al.
JOURNAL OF IMMUNOLOGY (2002)
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
H Hemmi et al.
NATURE IMMUNOLOGY (2002)
Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma
AB Bong et al.
DERMATOLOGY (2002)
NK- and CD8+ T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides
Y Kawarada et al.
JOURNAL OF IMMUNOLOGY (2001)
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
L Alexopoulou et al.
NATURE (2001)
Cutting edge: Role of toll-like receptor 9 in CpG DNA-induced activation of human cells
F Takeshita et al.
JOURNAL OF IMMUNOLOGY (2001)
Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition
S Bauer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Discrimination of bacterial lipoproteins by Toll-like receptor 6
O Takeuchi et al.
INTERNATIONAL IMMUNOLOGY (2001)
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5
F Hayashi et al.
NATURE (2001)
Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism
C Werts et al.
NATURE IMMUNOLOGY (2001)
A Toll-like receptor recognizes bacterial DNA
H Hemmi et al.
NATURE (2000)